The Effects of the JOBS Act on Biotech Startups
The 2015 JOBS Act, including Regulation A+, is driving the biotech industry forward. IPO volume in biotech has more than doubled since 2015, now accounting for almost 40% of US IPOs. Biotech companies are getting to their IPOs faster, at higher valuations, and using the money to fund further R&D, and hiring to support it.
Deregulating capital is creating jobs and saving lives.
Deregulating Innovation Capital: The Effects of the JOBS Act on Biotech Startups | CLS Blue Sky Blog
Under the JOBS Act, Congress and the SEC significantly reduced disclosure requirements and compliance costs for newly public companies.